Abridge revenue: a $117M ARR medical scribe valued at $5.3B
Abridge revenue reportedly reached $117M ARR in early 2025 (media-reported), as the AI medical scribe raised at $5.3B and expanded to 300+ health systems by 2026.
| Revenue | ~$9.75M/mo (calc, 2025)Calc: reported $117M ARR ÷ 12 Source, 2025-06 |
|---|---|
| Team size | Not disclosed |
| Pricing | Not disclosed |
| Founded | 2018 |
| Founder | Shiv Rao |
Abridge revenue comes from a job no doctor wants: writing up the visit after the patient leaves. The AI medical scribe listens to the conversation and drafts the clinical note. Its annualized recurring revenue reportedly reached $117M in the quarter before June 2025 (media-reported, SiliconANGLE citing The Information). That month investors valued it at $5.3B. By June 2026 it was running in more than 300 health systems, including Johns Hopkins and Northwestern Medicine (media-reported, Fortune).
What does Abridge’s AI scribe actually do?
Abridge records a medical visit, transcribes it and turns the important details into a structured note in the hospital’s electronic health record. SiliconANGLE describes the core as a Contextual Reasoning Engine that also drafts medical orders and generates ICD-10 and billing codes (SiliconANGLE). Shiv Rao, a practicing cardiologist (Fortune), cofounded the company in 2018 (Fortune). Fortune reports it now handles more than 100 million clinical conversations a year.
The customers are large health systems, not individual doctors. In July 2025 Rao cited 26,000 clinicians at Kaiser alone (Fortune).
How much ARR does Abridge make?
The only public revenue figure is $117M in annualized recurring revenue, reported by The Information for the quarter before Abridge’s June 2025 round (media-reported, SiliconANGLE). That works out to about $9.75M a month (calc). Abridge itself has not confirmed it or released a newer number. Pricing, current ARR and total revenue are not disclosed.
What the company does share is reach. It said it served more than 150 health systems in July 2025 (founder-reported, Fortune). Fortune counted more than 300 live a year later. Health-system contracts are large and slow to sign, so doubling that count in a year points to strong revenue growth, though the size of it is not public.
Why does Abridge call itself a revenue cycle company?
Abridge’s notes do more than save time; they help hospitals bill. The same conversation that becomes a clinical note also produces billing codes, and SiliconANGLE reported that the 2025 funding would focus on that feature (SiliconANGLE).
“we’re a revenue cycle company, along with the other things we do.” — Shiv Rao (founder-reported, Fortune)
In our reading, this is the key to Abridge’s pricing power. A tool that saves doctors time is a nice-to-have. A tool that helps the hospital capture revenue it would otherwise miss is something the finance team will pay for.
How has Abridge’s valuation changed?
Abridge’s valuation nearly doubled in four months and then held. Fortune says the February 2025 Series D valued it at $2.75B. In June 2025 Andreessen Horowitz led a $300M Series E, with Khosla Ventures, at $5.3B (founder-reported via SiliconANGLE). A $316M extension closed in April 2026 at the same $5.3B, bringing total funding to about $830M (media-reported, Fortune).
| Date | Round | Valuation | Source |
|---|---|---|---|
| Feb 2025 | Series D | $2.75B | Fortune |
| Jun 2025 | $300M Series E | $5.3B | SiliconANGLE |
| Apr 2026 | $316M Series E extension | $5.3B | Fortune |
How does Abridge compare with Freed and Harvey?
Abridge and Freed both sell AI scribes, but to opposite ends of medicine. Freed sells self-serve plans to small and independent practices at $39 to $119 a month (founder-reported, Freed). Sacra estimated Freed at $33M ARR in August 2026 (third-party estimate, Sacra), well below the $117M reported for Abridge a year earlier. Harvey is the closest match in another field: an AI tool sold to large professional organizations, which reported more than $100M ARR in August 2025 (founder-reported, Harvey).
In our view, the split is sales motion. Freed can sign a doctor in minutes with a credit card. Abridge has to win a hospital system, connect to its health record software and train thousands of clinicians. That is slower, but each contract is far larger, and the billing-code feature gives the buyer a financial reason to say yes. Harvey made a similar bet on big law firms.
OpenEvidence sells to the same doctors with a different model: it is free for clinicians and paid for by advertisers.
What lessons does Abridge offer founders in vertical AI?
- Tie the product to the buyer’s revenue. Abridge’s billing codes turn a time-saver into something the hospital’s finance team values.
- Enterprise healthcare is slow but sticky. Going from 150 to 300 health systems took a year, and each one is a large contract.
- Domain founders help. A cardiologist cofounder understands the note-writing burden from the inside.
- Leaked numbers fill the gap. Abridge’s only revenue figure comes from The Information, not the company, so treat it as reported, not confirmed.
Frequently asked questions
What is Abridge's revenue?
The Information reported that Abridge's annualized recurring revenue reached $117M in the quarter before its June 2025 funding round (media-reported via SiliconANGLE). That is about $9.75M a month (calc). Abridge has not published a newer figure, and total revenue is not disclosed.
What is Abridge's valuation?
Abridge was valued at $5.3B after a $300M Series E led by Andreessen Horowitz in June 2025 (founder-reported via SiliconANGLE), up from $2.75B in February 2025. A $316M extension in April 2026 kept the $5.3B valuation (media-reported, Fortune).
How much funding has Abridge raised?
Fortune put Abridge's total funding at about $830M in June 2026 (media-reported).
How does Abridge make money?
Abridge sells its ambient documentation software to health systems. CEO Shiv Rao told Fortune the company sees itself as a revenue cycle company, because its notes also produce the billing codes hospitals use to get paid (founder-reported, Fortune). Pricing is not disclosed.
Sources
- Medical AI startup Abridge closes $300M investment at $5.3B valuation – SiliconANGLE, 2025-06
- Abridge CEO Shiv Rao on raising $300 million, a prospective IPO and the future of healthcare – Fortune, 2025-07
- Abridge wants to be the operating system of medicine – Fortune, 2026-06